Illustrative estimate only - not verified by this sponsor. Contact the study team for actual compensation.
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
What happens when you apply
Reach out via phone or email to express interest
Brief call to discuss your health history
Medical screening at the research site
Begin your journey in the study
Inclusion Criteria: * Body Mass Index ≥ 25 and \< 40 kg/m\^2 * No serious medical problems or chronic diseases, specifically no type I or type II diabetes Exclusion Criteria: * Another disorder that contributes to gastrointestinal symptoms * History of intolerance and/or hypersensitivity to NK-1 receptor antagonists * History of intolerance and/or hypersensitivity to GLP-1 receptor agonists * Exposure to any investigational medication within the past 60 days
imaguineapig pulls live data from ClinicalTrials.gov (NIH/NLM).Illustrative estimate only - not verifiedPay estimates are approximate ranges based on study type and are not confirmed by sponsors — actual compensation may differ. Eligibility indicators use limited criteria (age, sex) only. We do not provide medical advice. Always contact the study team directly to confirm compensation, full eligibility, and risks before enrolling.